Theravance Biopharma (TBPH) Research & Development (2013 - 2026)
Theravance Biopharma (TBPH) reported Research & Development of $5.8 million for Q1 2026, down 49.1% year-over-year from $11.5 million in Q1 2025, and down 20.8% quarter-over-quarter from $7.4 million in Q4 2025.
Theravance Biopharma (TBPH) Research & Development (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of Research & Development data on file, last reported at $5.8 million in Q1 2026.
- Research & Development for Q1 2026 came in at $5.8 million, down 49.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $31.8 million (down 20.77% YoY), and the FY2025 annual result was $37.4 million, down 0.61% from the prior year.
- Research & Development slipped to $5.8 million in Q1 2026 per TBPH's latest filing, from $7.4 million in the prior quarter.
- Over five years, Research & Development peaked at $23.3 million in Q1 2022 and troughed at $5.8 million in Q1 2026.
- A 5-year average of $10.9 million and a median of $9.5 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development tumbled 77.44% in 2022, then gained 27.7% in 2025.
- A 5-year view of Research & Development shows it stood at $15.3 million in 2022, then plunged by 45.84% to $8.3 million in 2023, then gained by 13.71% to $9.5 million in 2024, then retreated by 22.14% to $7.4 million in 2025, then decreased by 20.8% to $5.8 million in 2026.
- Business Quant data shows TBPH's Research & Development at $5.8 million in Q1 2026, $7.4 million in Q4 2025, and $8.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 1.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -2.30 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -58.00 Mn |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | 5.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.83 Mn |
| Dec 31, 2025 | 7.36 Mn |
| Sep 30, 2025 | 8.11 Mn |
| Jun 30, 2025 | 10.49 Mn |
| Mar 31, 2025 | 11.45 Mn |
| Dec 31, 2024 | 9.45 Mn |
| Sep 30, 2024 | 9.27 Mn |
| Jun 30, 2024 | 9.95 Mn |
| Mar 31, 2024 | 8.97 Mn |
| Dec 31, 2023 | 8.31 Mn |
| Sep 30, 2023 | 8.31 Mn |
| Jun 30, 2023 | 9.43 Mn |
| Mar 31, 2023 | 14.57 Mn |
| Dec 31, 2022 | 15.35 Mn |
| Sep 30, 2022 | 9.87 Mn |
| Jun 30, 2022 | 14.92 Mn |
| Mar 31, 2022 | 23.25 Mn |
| Dec 31, 2021 | 31.23 Mn |
| Sep 30, 2021 | 43.74 Mn |
| Jun 30, 2021 | 51.09 Mn |